A Concordance Study Among 26 NGS Laboratories Participating in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Clinical Trial.
Academic Article
Overview
abstract
PURPOSE: NCI selected a network of CLIA-certified laboratories performing routine NGS tumor testing to identify patients for the NCI-MATCH trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. EXPERIMENTAL DESIGN: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from 8 cell lines and 2 clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for SNV, Indel, and CNV variant classes. RESULTS: We observed high concordance in variant detection between CL and DL for SNVs and Indels (Average Positive Agreement, APA>95.4% for all pairwise comparisons) but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2%82%) except between CL and 2 assays (APA=76.9 and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. CONCLUSIONS: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatics analysis.
